Literature DB >> 3620420

Cyclosporin therapy in Mooren's ulcer.

D Wakefield, L P Robinson.   

Abstract

Mooren's ulcer is a rare disease of presumed autoimmune aetiology. Some cases run a chronic severe course and fail to respond to local and systemic therapy. We report here such a case with bilateral Mooren's ulcer that failed to respond to local therapy with topical corticosteroids, silver nitrate, and conjunctival resection, as well as systemic immunosuppression with corticosteroids, cyclophosphamide, and azathioprine. Systemic cyclosporin (10 mg/kg/day) resulted in resolution of the corneal ulceration within two weeks of beginning treatment, and the patient has remained in remission after 15 months of therapy. Cyclosporin side effects included hirsutism, hypertension, increased blood levels of urea and creatinine, and abnormalities in liver function tests. All these resolved on reducing the dosage of cyclosporin. The results in this case suggest that cyclosporin is an effective agent in patients with severe sight threatening Mooren's ulcer.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3620420      PMCID: PMC1041189          DOI: 10.1136/bjo.71.6.415

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  10 in total

1.  Cellular immunity in Mooren's ulcer.

Authors:  B J Mondino; S I Brown; B S Rabin
Journal:  Am J Ophthalmol       Date:  1978-06       Impact factor: 5.258

2.  Circulating antibodies to corneal tissue in a patient suffering from Mooren's ulcer (ulcus rodens corneae).

Authors:  O L Schaap; T E Feltkamp; A C Breebaart
Journal:  Clin Exp Immunol       Date:  1969-10       Impact factor: 4.330

Review 3.  The effects of cyclosporin A on the immune system.

Authors:  E M Shevach
Journal:  Annu Rev Immunol       Date:  1985       Impact factor: 28.527

4.  Percutaneous transluminal coronary angioplasty.

Authors: 
Journal:  Lancet       Date:  1979-08-04       Impact factor: 79.321

5.  Autoimmune phenomenon in Mooren's ulcer.

Authors:  S I Brown; B J Mondino; B S Rabin
Journal:  Am J Ophthalmol       Date:  1976-12       Impact factor: 5.258

6.  Cyclosporin-induced nephrotoxicity. Inevitable and intractable?

Authors:  T B Strom; R Loertscher
Journal:  N Engl J Med       Date:  1984-09-13       Impact factor: 91.245

7.  Immunosuppressive therapy for external ocular inflammatory disease.

Authors:  C S Foster
Journal:  Ophthalmology       Date:  1980-02       Impact factor: 12.079

8.  Cyclosporin A therapy in the treatment of intraocular inflammatory disease resistant to systemic corticosteroids and cytotoxic agents.

Authors:  R B Nussenblatt; A G Palestine; C C Chan
Journal:  Am J Ophthalmol       Date:  1983-09       Impact factor: 5.258

9.  Pathogenesis of Mooren's ulcer: some new concepts.

Authors:  P I Murray; A H Rahi
Journal:  Br J Ophthalmol       Date:  1984-03       Impact factor: 4.638

10.  Autoimmune phenomena of the external eye.

Authors:  B J Mondino; S I Brown; B S Rabin
Journal:  Ophthalmology       Date:  1978-08       Impact factor: 12.079

  10 in total
  6 in total

1.  Bilateral Mooren's ulcer in six patients: diagnosis, surgery and histopathology.

Authors:  Christos D Kalogeropoulos; Vassiliki D Malamou-Mitsi; Miltiadis B Aspiotis; Konstantinos G Psilas
Journal:  Int Ophthalmol       Date:  2004-01       Impact factor: 2.031

2.  Topical treatment of severe corneal ulcers with cyclosporin A.

Authors:  M Zierhut; H J Thiel; E G Weidle; R Waetjen; U Pleyer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1989       Impact factor: 3.117

3.  Cyclosporin therapy for severe scleritis.

Authors:  D Wakefield; P McCluskey
Journal:  Br J Ophthalmol       Date:  1989-09       Impact factor: 4.638

Review 4.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

Review 5.  Rapid deterioration of Mooren's ulcers after conjunctival flap: a review of 2 cases.

Authors:  Saiqun Li; Yuqing Deng; Caiyuan Du; Haixiang Huang; Jing Zhong; Ling Chen; Bowen Wang; Jin Yuan
Journal:  BMC Ophthalmol       Date:  2017-06-15       Impact factor: 2.209

6.  Amniotic membrane transplantation ineffective as additional therapy in patients with aggressive Mooren's ulcer.

Authors:  Maurice Schallenberg; Henrike Westekemper; Klaus-Peter Steuhl; Daniel Meller
Journal:  BMC Ophthalmol       Date:  2013-12-17       Impact factor: 2.209

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.